A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel

European Journal of Contraception and Reproductive Health Care

Volumn 5, Issue 2, 2000, Pages 124-134

  Foidart, J M ^d   Wuttke, W ^a   Bouw, G M ^b   Gerlinger, C ^c   Heithecker, R ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Ziekenhuis Geldorse Vallei   (Netherlands)

^c BAYER PHARMA AG   (Germany)

^d Centre Hospitalier Regional de La Citadelle   (Belgium)

Author keywords

Antiandrogenic effect; Antimineralocorticoid effect; Drospirenone; Natural progesterone; Oral contraceptive; Tolerance

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONTRACEPTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERANCE; DYSMENORRHEA; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTICENTER STUDY; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0000275817     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/13625180008500387     Document Type: Article

References (11)

1. 1. Oelkers WKH. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996;61:166-71
2. 2. Rosenberg M. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179:577-82
3. 3. Oddens BJ. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning and sterilization among 1466 women. Contraception 1999;59:277-86
4. 4. Muhn P, Krattenmacher R, Beier S, et al. Drospirenone, a novel progestogen with antimineralocorticoid and antiandrogenic activity. Contraception 1995;51: 99-110
5. 5. Fuhrmann U, Krattenmacher R, Slater EP, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243-51
6. 6. Pollow K, Jucham N, Elger W, Jacobi N, Hoffmann G, Hobus V. Dihydrospirorenone (ZK30595): a novel synthetic progestagen - characterization of binding to different receptor proteins. Contraception 1992;46: 561-74
7. 7. Kuhl H. Drugs 1996:51;188-215
8. 8. Oelkers WKH, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991;73:837-42
9. 9. Oelkers WKH, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995;80:1816-21
10. 10. Rosenbaum P, Schmidt W, Helmerhorst FM, et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur J Contracept Reprod Health Care 2000;5:16-24
11. 11. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care 2000;5:25-34